Journal ArticleDOI
Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Stacey L. Martiniano,Brandie D. Wagner,Adrah Levin,Jerry A. Nick,Scott D. Sagel,Charles L. Daley +5 more
Reads0
Chats0
TLDR
Clofazimine was a safe, reasonably tolerated, and active oral drug for NTM infection in the authors' heterogeneous population of pediatric and adult CF and non‐CF patients and should be considered as an alternative drug for treatment of NTM disease.About:
This article is published in Chest.The article was published on 2017-10-01. It has received 99 citations till now. The article focuses on the topics: Clofazimine & Nontuberculous mycobacteria.read more
Citations
More filters
Journal ArticleDOI
NTM drug discovery: status, gaps and the way forward
TL;DR: The current status of NTM drug development is summarized, knowledge gaps and scientific obstacles are highlighted, and strategies to reduce biological uncertainties and to begin to populate a N TM drug pipeline with attractive leads and drug candidates are proposed.
Journal ArticleDOI
Non-tuberculous mycobacterial pulmonary disease
TL;DR: Current knowledge on the epidemiology, aetiology and diagnosis of nontuberculous mycobacterial pulmonary disease is summarized and the treatment of two of the most clinically significant species, the M. avium and M. abscessus complexes are discussed, with a focus on refractory disease and novel therapies.
Journal ArticleDOI
Mycobacterium abscessus pulmonary disease: Individual patient data meta-analysis
Nakwon Kwak,Margareth Pretti Dalcolmo,Charles L. Daley,Geoffrey Eather,Regina Gayoso,Naoki Hasegawa,Byung Woo Jhun,Won-Jung Koh,Ho Namkoong,Jimyung Park,Rachel Thomson,Jakko van Ingen,Sanne M.H. Zweijpfenning,Jae-Joon Yim +13 more
TL;DR: An individual patient data meta-analysis based on studies reporting treatment outcomes for MAB-PD found the use of azithromycin, amikacin or imipenem was associated with better outcomes for patients with M. abscessus, and the choice among these drugs was not associated with treatment outcomes.
Journal ArticleDOI
Mycobacterium avium Complex Disease.
TL;DR: Treatment outcomes for many patients with Mycobacterium avium complex (MAC) disease remain suboptimal, so new drugs and treatment regimens are greatly needed.
Journal ArticleDOI
Treatment of Mycobacterium avium Complex Pulmonary Disease.
TL;DR: New therapies, including clofazimine, inhaled amikacin, and bedaquiline, have shown promising results for the treatment of MAC pulmonary disease, especially in patients with treatment failure or macrolide-resistantMAC pulmonary disease.
References
More filters
Journal ArticleDOI
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
David E. Griffith,Timothy R. Aksamit,Barbara A. Brown-Elliott,Antonino Catanzaro,Charles L. Daley,Fred M. Gordin,Steven M. Holland,Robert Horsburgh,Gwen A. Huitt,Michael F. Iademarco,Michael D. Iseman,Kenneth N. Olivier,Stephen J. Ruoss,C. Fordham von Reyn,Richard J. Wallace,Kevin L. Winthrop +15 more
TL;DR: Diagnostic Criteria of Nontuberculous Mycobacterial Lung Disease Key Laboratory Features of N TM Health Careand Hygiene-associated Disease Prevention Prophylaxis and Treatment of NTM Disease Introduction Methods.
Journal ArticleDOI
Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review.
TL;DR: Host factors important to the current epidemiology of NTM pulmonary disease include thoracic skeletal abnormalities, rheumatoid arthritis, and use of immunomodulatory drugs.
Journal ArticleDOI
Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.
Kenneth N. Olivier,David J. Weber,Richard J. Wallace,Ali R. Faiz,Ji-Hyun Lee,Yansheng Zhang,Barbara A. Brown-Elliot,Allison Handler,Rebecca W. Wilson,Michael S. Schechter,Lloyd J. Edwards,Subha Chakraborti,Michael R. Knowles +12 more
TL;DR: NTM are common in patients with CF, but neither person-to-person nor nosocomial acquisition explained the high prevalence, and older age was the most significant predictor for isolation of NTM.
Journal ArticleDOI
Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus.
Won-Jung Koh,Kyeongman Jeon,Nam Yong Lee,Bum Joon Kim,Yoon Hoh Kook,Seung Heon Lee,Young Kil Park,Chang Ki Kim,Sung Jae Shin,Gwen A. Huitt,Charles L. Daley,O Jung Kwon +11 more
TL;DR: In this paper, the authors compared clinical features and treatment outcomes between patients with M. abscessus lung disease and those with massiliense lung disease, and found that the clinical and radiographic manifestations of disease caused by each species were similar.
Journal ArticleDOI
The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS).
C. R. Horsburgh,Selik Rm +1 more
TL;DR: It is concluded that DNTM is acquired by unpreventable environmental exposures that adversely affects survival of AIDS patients and effective therapeutic agents must be vigorously sought.
Related Papers (5)
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
David E. Griffith,Timothy R. Aksamit,Barbara A. Brown-Elliott,Antonino Catanzaro,Charles L. Daley,Fred M. Gordin,Steven M. Holland,Robert Horsburgh,Gwen A. Huitt,Michael F. Iademarco,Michael D. Iseman,Kenneth N. Olivier,Stephen J. Ruoss,C. Fordham von Reyn,Richard J. Wallace,Kevin L. Winthrop +15 more
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
R. Andres Floto,R. Andres Floto,Kenneth N. Olivier,Lisa Saiman,Charles L. Daley,Jean-Louis Herrmann,Jerry A. Nick,Peadar G. Noone,Diana Bilton,Paul A. Corris,Ronald L. Gibson,Sarah E. Hempstead,Karsten Koetz,Kathryn A. Sabadosa,Isabelle Sermet-Gaudelus,Alan R. Smyth,Jakko van Ingen,Richard J. Wallace,Kevin L. Winthrop,Bruce C. Marshall,Charles S. Haworth +20 more